Stock CELLECT BIOTECHNOLOGY LTD
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Cellect Biotechnology Ltd

Equities

IL0002410186

End-of-day quote TEL AVIV STOCK EXCHANGE
Other stock markets
- ILa - Intraday chart for Cellect Biotechnology Ltd

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cellect Biotechnology Ltd : Provides Corporate Update and Reports First Quarter 2017 Financial Results
PR
Cellect Gets Green Light From FDA For ApoGraft IND Submission in the U.S.
GL
Cellect Receives Notice of Intention to Grant from European Patent Office for Patent Protecting Company’s Technology in Multiple Indications
GL
Cellect Biotechnology : Successful First Cancer Patient Stem Cell Transplant
PU
Cellect Announces Successful First Cancer Patient Stem Cell Transplant
GL
Cellect Biotechnology : Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
PU
Cellect Biotechnology : Michael Berelowitz MD., Former Head, Clinical Development and Medical Affairs, Pfizer Specialty Care Business Unit Joins Cellect’s Board of Directors
PU
Cellect Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results
GL
Michael Berelowitz MD., Former Head, Clinical Development and Medical Affairs, Pfizer Specialty Care Business Unit Joins Cellect’s Board of Directors
GL
Cellect Biotechnology : Announces Positive Clinical Trial Results
PU
Cellect to Ring the NASDAQ Stock Market Opening Bell on Friday, February 24th
GL
World-Renowned Stem Cell Transplantation Expert joins Cellect’s Advisory Board
GL
Cellect Announces Positive Clinical Trial Results
GL
Cellect Biotechnology : First Cancer Patient Treated In Phase I/II Trial Management expects additional positive upcoming results from its trial in healthy volunteers
PU
Cellect Biotechnology : Dual-Listed Cellect to Voluntarily File for Delisting from Tel Aviv Stock Exchange Company’s Shares to Continue Trading Only on NASDAQ Stock Exchange in US
PU
Dual-Listed Cellect to Voluntarily File for Delisting from Tel Aviv Stock Exchange
GL
Dr. Yaron Pereg Appointed as New Chief Development Officer
GL
Cellect Receives Patent Notice of Allowance from US Patent & Trademark Office Protecting Company’s Technology in Multiple Key Indications
GL
Major Shareholder Buying Shares
GL
Cellect Announces Appointment of Eyal Leibovitz, Experienced Life Sciences Industry and Financial Executive, as Chief Financial Officer
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Cellect Biotechnology Ltd